Chimeric IgG1 Mouse Models for FcRn Pharmacokinetic Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mouse models used for preclinical development of IgG-based biologics lack an endogenous source of human IgG, which limits their ability to accurately model human antibody recycling and pharmacokinetics.
Innovation Solution
Genetically modifying the hFCGRT Tg32 strain to produce human IgG1 Fc-mouse IgG Fab2 chimeric antibodies at physiologically relevant levels, allowing for competition with exogenous humanized mAbs for binding to human FcRn.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FCGRT-humanized mice (Tg32 strain) are used to model human IgG-based biologics, then the recycling pathway can be evaluated, but the model lacks an endogenous source of human IgG to provide competitive conditions
Solution Approach 1:
The patent introduces chimeric IgG1 molecules as an intermediary component that bridges the gap between mouse and human systems. These chimeric molecules contain human IgG1 Fc regions that can bind to human FcRn, providing the necessary competitive environment without requiring complete humanization of the mouse model. This intermediary approach resolves the contradiction by adding only the essential human element (Fc region) needed for reliable pharmacokinetic evaluation.
Solution Approach 2:
The patent applies local quality by humanizing only the Fc region of the IgG1 antibody rather than the entire molecule. The chimeric IgG1 contains mouse variable regions and constant regions 1 and 2, but human constant region 3 (Fc region), which is the critical component for FcRn binding. This localized humanization provides the necessary competitive environment while minimizing genetic modification complexity.
2Measurement precision
If endogenous human IgG is introduced to create competitive conditions, then pharmacokinetic accuracy is improved, but the model complexity and difficulty of implementation increase
Solution Approach 1:
The patent applies partial action by introducing only the essential human Fc region component needed for competitive binding to FcRn, rather than introducing complete human IgG. The chimeric IgG1 molecules provide sufficient human Fc characteristics to create accurate competitive conditions for pharmacokinetic evaluation, while avoiding the complexity of generating fully human IgG-producing mice through complete human immune system engraftment.
3Measurement precision
If the mouse model is genetically modified to produce chimeric IgG1, then the serum half-life prediction accuracy is improved, but the genetic modification process becomes more complex
Solution Approach 1:
The patent applies parameter changes by modifying the structural composition of the endogenous IgG1 from purely mouse to chimeric (mouse-human hybrid). Specifically, the human Fc region parameter is introduced into the IgG1 molecule, which fundamentally changes its binding properties to human FcRn. This parameter change enables accurate serum half-life prediction while using relatively straightforward genetic modification techniques to create the chimeric structure.
Data Source
AI summary
The present disclosure provides improved humanized IgG1 FCRN mouse models for use, for example, in estimating serum half-life of therapeutic proteins such as monoclonal antibodies.